Obesity Rates
60 articles on Obesity Rates, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Ozempic, Wegovy & Mounjaro: Navigating the GLP-1 Weight Loss Revolution
The global surge in GLP-1 medications for weight loss has sparked a vital conversation in India. While innovators like Nithin Kamath highlight affordability and potential, industry leaders like Kiran Mazumdar-Shaw urge careful consideration. This article delves into the nuances of these transformative drugs, their benefits, the hurdles to long-term adoption, and what they mean for your health journey.
7 min read
Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.
8 min read
Beyond the Needle: Why Wegovy Alone Can't Cure New Zealand's Obesity Crisis
As New Zealand considers public funding for Wegovy, experts warn that medication alone cannot solve the obesity epidemic driven by complex environmental and social factors.
8 min read
Ozempic and the Shift: Real Data on America's Obesity Rates
New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.
7 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
Military's $700M GLP-1 Spending: Weight Loss Solutions or Taxpayer Burden?
The U.S. military has spent nearly $726 million on GLP-1 medications since 2021. This article delves into the controversy surrounding this expenditure, examining the obesity crisis within the armed forces and the debate over these weight-loss drugs.
7 min read
Pfizer's Xianweiying GLP-1 Weight Loss Drug Pre-Order in China
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
5 min read
Indian Companies Rush to Make Generic GLP-1s Like Semaglutide
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
4 min read
Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
5 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains
Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.
5 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
Emcure Slashes Poviztra Price 55% in Semaglutide India Price War
Emcure Pharmaceuticals has dramatically reduced Poviztra prices by 55% for the starting dose, fueling a semaglutide price war in India after patent exclusivity lapsed. This move positions the branded pen injector competitively against generics priced as low as Rs 1,200-1,500 per month. With obesity rates rising, these changes could widen access to this proven weight-management therapy.
4 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
Novo Nordisk, key supplier of GLP-1 drugs like Ozempic and Wegovy, has appointed Mars CEO Poul Weihrauch as a board observer. This move highlights the growing impact of weight-loss medications on food consumption habits. As GLP-1 use rises, food giants are adapting to shifting snack demands.
5 min read
Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
5 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
Alkem Launches Affordable Semaglutide Injection in India at Rs450 Weekly
Alkem Laboratories is revolutionizing GLP-1 access in India with its new semaglutide injection, priced at just Rs450 per week. Branded as Semasize, Obesema, and Hepaglide, this once-weekly therapy targets Type 2 diabetes and chronic weight management. Learn about its approvals, innovative pens, and potential impact on affordable care.
5 min read
Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide in India
Indian pharma leaders Sun Pharma, Dr Reddy's, and Glenmark have launched generic semaglutide injections in India, slashing costs compared to Ozempic and Wegovy after patent expiry. With weekly prices starting at Rs 325, these options make GLP-1 therapy accessible for type 2 diabetes and weight management. Zydus joins with more affordable brands, transforming treatment affordability.
5 min read
Natco Pharma Starts Semaglutide Price War: Generic at ₹1,290/Month, 90% Cheaper
Natco Pharma is shaking up India's weight-loss drug market with its generic semaglutide priced at just ₹1,290 per month—90% cheaper than Novo Nordisk's Ozempic. Launching Saturday after patent expiry, this move invites competition from Sun Pharma, Dr Reddy's, and others. Patients gain affordable access to this GLP-1 powerhouse for weight management and diabetes.
5 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
India GLP-1 Weight-Loss Drug Market to Reach ₹5,000 Crore by 2030: CareEdge
India's GLP-1 and weight-loss drug market is set for explosive growth, expanding fivefold to ₹5,000 crore by 2030, according to CareEdge Ratings. Semaglutide's patent expiry will trigger sharp price cuts, boosting access amid surging demand from type 2 diabetes patients. However, generic makers face patent battles, manufacturing hurdles, and safety scrutiny.
5 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read
Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
4 min read
CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
4 min read
Govt Cautions Pharma Cos on Surrogate Ads for GLP-1 Drugs
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
6 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
Aspen Plans Mounjaro Rollout in Sub-Saharan Africa
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
4 min read
Semaglutide Production Cost: $3/Month Could Expand Access to Obesity & Diabet...
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
5 min read
Denmark's Obesity Rate Stalls in Wegovy-Maker Novo's Home Market
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
4 min read
Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
6 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read
Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
6 min read
Eris Lifesciences Partners Natco for Semaglutide in India
Eris Lifesciences has partnered with Natco Pharma to bring semaglutide, a key GLP-1 receptor agonist, to the Indian market for Type 2 diabetes management. With CDSCO approval secured, the launch is set for March 2026. This move strengthens Eris's diabetes portfolio amid rising diabetes cases in India.
5 min read
Forget Ozempic: Intuitive Surgical Thrives No Matter GLP-1 Winner
Wall Street fixates on GLP-1 giants like Novo Nordisk's Ozempic and Eli Lilly, but Intuitive Surgical continues to thrive with its da Vinci surgical robots. With 11,106 systems installed by end of 2025 and procedures up 18%, this device maker is set for growth regardless of the weight loss drug race. Learn why investors should consider ISRG shares.
5 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read
American Girl Dolls Get 'Ozempic' Makeover for Modern Era, Public Unimpressed
American Girl Dolls have undergone a controversial 'Ozempic' makeover, with slimmer bodies aimed at the 'modern era'—but many parents and influencers are far from impressed. The redesign highlights the cultural impact of GLP-1 medications like Ozempic on body ideals. Explore the debate, drug mechanisms, and health considerations.
5 min read
Obesity Rates Rising to 50% by 2030 Despite GLP-1s: What It Means
Despite the buzz around GLP-1 medications like Wegovy and Zepbound, obesity rates in the U.S. are projected to hit nearly 50% by 2030, per a New England Journal of Medicine study. Severe obesity (BMI 40+) continues to rise, highlighting disparities in food access and demographics. UVA expert Dr. Cate Varney breaks down what this means for public health and patients.
6 min read
Semaglutide Nasal Spray: Affordable Weight Loss Option Coming Soon
A nasal spray version of semaglutide, the active ingredient in Ozempic and Wegovy, could soon offer an affordable alternative for weight loss. Chinese firm Shanghai Shiling Pharmaceutical is advancing trials, aiming for global markets by 2028 amid soaring demand. This development aligns with Novo Nordisk's upcoming patent loss in China, paving the way for cheaper generics.
5 min read
China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
4 min read
HSE's €500k Daily Spend on Ozempic & Saxenda: Key Facts
Ireland's HSE shelled out over €500k daily last year on GLP-1 injections like Ozempic and Saxenda for patients on free schemes. With usage surging 33% since 2023, explore the spending breakdown, regional variations, and what this means for access to these diabetes and weight loss treatments. Understand the science, eligibility, and future of drugs like Mounjaro.
4 min read
GLP-1 Market Boom to $299B by 2033: Drugs & Insights
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
4 min read
GLP-1 Drugs: Slimming Waists and Airlines' Fuel Costs
The GLP-1 drug boom isn't just transforming bodies—it's potentially lightening airplane loads and cutting airline fuel bills. Analysts predict a slimmer society could boost profits, but what's the real story behind these medications? This guide dives into the science, data, and broader implications for your health journey.
4 min read
Novo Nordisk vs Eli Lilly: GLP-1 Drugs Showdown
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
5 min read
GLP-1 Revolution: Ozempic, Wegovy, Mounjaro Rise
GLP-1 injections like Ozempic, Wegovy, and Mounjaro have exploded from niche diabetes therapies to cultural icons in weight management. While offering profound metabolic benefits, their rapid mainstreaming raises questions about proper use, side effects, and societal pressures. This guide unpacks the science, real-world stories, and future implications.
4 min read
Scotland GLP-1 Costs Surge: Mounjaro Price Hike Impact
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
4 min read
Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates
CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.
2 min read
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
2 min read
Ozempic Generic: Semaglutide Prices Drop to $70
Semaglutide prices are set to plummet from $200 to $70 per dose as Ozempic goes generic. This affordability shift could lower obesity rates and prompt wider insurance coverage. Explore the weighty consequences for GLP-1 users worldwide.
1 min read
CMS Introduces Initiative to Enhance GLP-1 Availability in Medicaid and Medicare Part D
A novel CMS demonstration program seeks to broaden access to GLP-1 receptor agonists for individuals in Medicare Part D and Medicaid, aiming to address weight management and metabolic health. While it promises negotiations with manufacturers for reduced prices, experts remain skeptical about its widespread effectiveness. The initiative builds on prior drug pricing efforts and includes provisions for lifestyle support, with launch timelines set for 2026.
5 min read
Half of Americans Aspire to Lose Weight
As the new year begins, many Americans reflect on their weight goals, with 52% expressing a wish to shed pounds while just 26% are making real efforts. Women are more likely than men to perceive themselves as overweight and desire change. Long-term data shows consistent patterns in self-reported weight and ideals.
4 min read
GLP-1's Impact: Forecasting the Food and Beverage Sector in 2026
The increasing use of GLP-1 drugs is reshaping the food and beverage industry. Circana's research highlights how retailers and manufacturers can adapt to meet the evolving needs of health-conscious consumers.
6 min read
Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly
The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.
2 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read